-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Terns Pharma, Raises Price Target to $35

Benzinga·11/19/2025 17:51:36
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Terns Pharma (NASDAQ:TERN) with a Buy and raises the price target from $28 to $35.